Menaquinone-7 Vitamin K2-7; Vitamin K2(35; Vitamin MK-7)|cas:2124-57-4|西域试剂

Menaquinone-7 Vitamin K2-7; Vitamin K2(35; Vitamin MK-7),98.0%

产品编号：Bellancom-112499| CAS NO：2124-57-4| 分子式：C₄₆H₆₄O₂| 分子量：649.00

Menaquinone-7 (Vitamin K2-7) 是维生素K2家族的成员，最早作为抗出血因子被发现。Menaquinone-7 (Vitamin K2-7)是Gla-蛋白羧化反应中最具生物活性的辅因子。补充Menaquinone-7 (Vitamin K2-7) 也是激活Gla基质蛋白并干预钙化性主动脉瓣狭窄(CAVS)进展的一种药理选择。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-112499	￥1000.00	杭州北京（现货）
Bellancom-112499	￥1400.00	杭州北京（现货）
Bellancom-112499	￥2900.00	杭州北京（现货）
Bellancom-112499	￥4900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Menaquinone-7 Vitamin K2-7; Vitamin K2(35; Vitamin MK-7)

产品介绍

Menaquinone-7 (Vitamin K2-7) 是一种具有口服活性的维生素 K2 家族的成员，最早作为抗出血因子被发现。Menaquinone-7 对体外破骨细胞的骨吸收有抑制作用，并对老年雌性大鼠股骨组织的骨形成有刺激作用。Menaquinone-7 在预防衰老引起的骨质退化方面具有较好的研究潜力。Menaquinone-7 也是激活 Gla 基质蛋白并干预钙化性主动脉瓣狭窄 (CAVS) 进展的一种药理选择。

生物活性

Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS)^[4]^[5].

体外研究

Menaquinone-7 (0.01-10 µM; 7 days) inhibits osteoclast-like cell formation in marrow cultures.
Menaquinone-7 (10 µM) promotes the expression of tenascin C and increases phosphorylated Smad1 level in MC3T3E1 cells.
Menaquinone-7 (1, 10 µM) significantly enhances the anabolic effect on the femoral calcium content in the presence of phytoestrogen genistein (1, 10 µM).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Marrow cells (from 3-week-old male wistar rats; PTH/PGE₂ stimulated)
Concentration:	0.01-10 µM
Incubation Time:	7 days
Result:	Significantly decreased the number of TRACP-positive MNCs stimulated by PTH or PGE2.

体内研究
(In Vivo)

Menaquinone-7 (18.1 mg/100 g diet; in animal feedings; 24 days) shows a preventive effect on bone loss in ovariectomized rats^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Wistar rats (5-week-old; ovariectomized (OVX) rats model)^[5].
Dosage:	18.1 mg/100 g diet
Administration:	In animal feedings; 24 days
Result:	Had a preventive effect on OVX-induced bone loss.

体内研究

Menaquinone-7 (18.1 mg/100 g diet; in animal feedings; 24 days) shows a preventive effect on bone loss in ovariectomized rats^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Wistar rats (5-week-old; ovariectomized (OVX) rats model)^[5].
Dosage:	18.1 mg/100 g diet
Administration:	In animal feedings; 24 days
Result:	Had a preventive effect on OVX-induced bone loss.

体内研究

Menaquinone-7 (18.1 mg/100 g diet; in animal feedings; 24 days) shows a preventive effect on bone loss in ovariectomized rats^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Wistar rats (5-week-old; ovariectomized (OVX) rats model)^[5].
Dosage:	18.1 mg/100 g diet
Administration:	In animal feedings; 24 days
Result:	Had a preventive effect on OVX-induced bone loss.

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (7.70 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5408 mL	7.7042 mL	15.4083 mL
5 mM	0.3082 mL	1.5408 mL	3.0817 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 0.54 mg/mL (0.83 mM); Suspended solution; Need ultrasonic

此方案可获得 0.54 mg/mL (0.83 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 5.4 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.54 mg/mL (0.83 mM); Clear solution

此方案可获得 ≥ 0.54 mg/mL (0.83 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 5.4 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。